These findings identified a negative regulatory mechanism between ACOX1 and miR-103-3p that promotes the pathogenesis of NAFLD and suggested that inhibition of miR-103-3p may be a potential treatment strategy for NAFLD. This evidence concerns the gene ACOX1 and metabolic dysfunction-associated steatotic liver disease.